Roth Capital Initiates Coverage On Bicycle Therapeutics with Buy Rating, Announces $17 Price Target

Roth Capital initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Buy rating and a $17 price target.

Benzinga · 11/14/2019 11:04

Roth Capital initiates coverage on Bicycle Therapeutics (NASDAQ:BCYC) with a Buy rating and a $17 price target.